Posted by Michael Wonder on 27 Jun 2025
Schrödinger receives fast track designation for SGR-1505 for the treatment of relapsed/refractory Waldenström's macroglobulinemia
27 June 2025 - Demonstrates the potential of SGR-1505 as a novel approach for diseases with high unmet medical need.
Schrödinger today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a fast track product by the US FDA for the treatment of adult patients with Waldenström's macroglobulinemia that have failed at least two lines of therapy, including a Bruton’s tyrosine kinase inhibitor.
